TY - JOUR
T1 - Bifurcation stenting
T2 - Current strategies and new devices
AU - Latib, A.
AU - Colombo, A.
AU - Sangiorgi, G. M.
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/3
Y1 - 2009/3
N2 - Based on the results of numerous randomised trials, the provisional approach of implanting one stent on the main branch has become the default approach to most bifurcation lesions. However, bifurcation intervention still remains technically challenging. Dedicated bifurcation stents have been designed to specifically treat coronary bifurcations with the aim of dealing with some of the shortcomings of the conventional percutaneous approach to bifurcation intervention. Most of the devices are aimed at facilitating the provisional approach. They are an exciting and innovative technology that may further simplify the management and current approach to bifurcation treatment. Currently, 11 devices are available that have either completed or are currently undergoing First-In-Man trials. The development of more drug-eluting platforms and larger studies with control groups demonstrating their clinical applicability, efficacy and safety are required before they are widely incorporated into daily practice.
AB - Based on the results of numerous randomised trials, the provisional approach of implanting one stent on the main branch has become the default approach to most bifurcation lesions. However, bifurcation intervention still remains technically challenging. Dedicated bifurcation stents have been designed to specifically treat coronary bifurcations with the aim of dealing with some of the shortcomings of the conventional percutaneous approach to bifurcation intervention. Most of the devices are aimed at facilitating the provisional approach. They are an exciting and innovative technology that may further simplify the management and current approach to bifurcation treatment. Currently, 11 devices are available that have either completed or are currently undergoing First-In-Man trials. The development of more drug-eluting platforms and larger studies with control groups demonstrating their clinical applicability, efficacy and safety are required before they are widely incorporated into daily practice.
UR - http://www.scopus.com/inward/record.url?scp=61949298609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61949298609&partnerID=8YFLogxK
U2 - 10.1136/hrt.2008.150391
DO - 10.1136/hrt.2008.150391
M3 - Review article
C2 - 18812408
AN - SCOPUS:61949298609
SN - 1355-6037
VL - 95
SP - 495
EP - 504
JO - Heart
JF - Heart
IS - 6
ER -